**Core Concept**
In hyperparathyroidism, a radionuclide scan, specifically a Technetium-99m (99mTc) sestamibi scan, is used to localize parathyroid adenomas or hyperplasia. This scan exploits the increased metabolic activity of abnormal parathyroid tissue, which takes up the radioactive tracer.

**Why the Correct Answer is Right**
The correct answer is related to the increased mitochondrial activity in parathyroid adenomas, which leads to increased uptake of 99mTc sestamibi. This is because parathyroid adenomas have increased mitochondrial activity, which is associated with increased cellular metabolism and increased uptake of the radioactive tracer. The scan exploits this difference to identify abnormal parathyroid tissue.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option may be tempting, but it is not directly related to the radionuclide scan finding in hyperparathyroidism. While parathyroid hormone (PTH) levels are elevated in hyperparathyroidism, the scan is not directly measuring PTH levels.
* **Option B:** This option is incorrect because it does not accurately describe the radionuclide scan finding in hyperparathyroidism. A sestamibi scan shows increased uptake in parathyroid adenomas, not decreased.
* **Option D:** This option is incorrect because it is related to a different imaging modality (ultrasound) and not directly related to the radionuclide scan finding in hyperparathyroidism.

**Clinical Pearl / High-Yield Fact**
A key point to remember is that a sestamibi scan can help identify parathyroid adenomas or hyperplasia, which can be responsible for hyperparathyroidism. This is particularly useful in patients with primary hyperparathyroidism, where the scan can guide surgical intervention.

**Correct Answer:** C. Increased uptake of 99mTc sestamibi in parathyroid adenomas.